前列腺癌症分层中新型微小RNA血清组的筛选和验证。

IF 2.7 2区 医学 Q2 UROLOGY & NEPHROLOGY
Anveshika Manoj , Mohammad K. Ahmad , Gautam Prasad , Durgesh Kumar , Abbas A. Mahdi , Manoj Kumar
{"title":"前列腺癌症分层中新型微小RNA血清组的筛选和验证。","authors":"Anveshika Manoj ,&nbsp;Mohammad K. Ahmad ,&nbsp;Gautam Prasad ,&nbsp;Durgesh Kumar ,&nbsp;Abbas A. Mahdi ,&nbsp;Manoj Kumar","doi":"10.1016/j.prnil.2023.06.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Owing to the heterogeneous nature of prostate cancer (PCa) and errors in the characterization of the disease, researchers have been trying to unveil molecular biomarkers like microRNA (miRNA) as diagnostic markers. The purpose of our study is to demonstrate the precision of a panel of miRNAs as biomarkers with diagnostic potential for risk stratification.</p></div><div><h3>Materials and methods</h3><p>The present study demonstrates the comparative expression profiles of miRNA-141,-1290,-100, and -335 in both tissue and serum, including Benign Prostate Hyperplasia (BPH) and PCa, with healthy volunteers. Firstly, we demonstrate the expression of all miRNAs in the discovery cohort, including metastasis and benign tissue, and later validate their non-invasive diagnostic potential in BPH and PCa with healthy volunteers. MiRNA was isolated from tissue and serum to be quantified by RT-PCR and analyzed for biomarker potential by receiver operating characteristic (ROC) curve analysis, followed by targetome analysis of each miRNA.</p></div><div><h3>Results</h3><p>Among the non-invasive miRNA assessed, it was seen that miRNA 141 (<em>P</em> = 0.0003) and miRNA 1290 (<em>P</em> &lt; 0.0001) are oncogenic with significantly higher expression, while miRNA 100 (<em>P</em> = 0.0002) and miRNA 335 are tumor suppressor, in PCa as compared to controls. While for BPH, miRNA 141 (<em>P</em> = 0.003) and miRNA 335 (<em>P</em> = 0.0002) were found to be significantly oncogenic and tumor suppressors, respectively. The analysis of the ROC curve of panel miRNAs (miRNA-141,-1290, and -100) portrayed a significant area under the curve with greater sensitivity and specificity. Moreover, in-silico prediction of their respective targetomes represents their extensive involvement in PCa progression and various other cascades that aid in PCa networks.</p></div><div><h3>Conclusions</h3><p>To the best of our knowledge, we are going to report for the first time this panel of miRNA that can be used to accurately and efficiently diagnose BPH and PCa patients from healthy males.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/95/main.PMC10513910.pdf","citationCount":"0","resultStr":"{\"title\":\"Screening and validation of novel serum panel of microRNA in stratification of prostate cancer\",\"authors\":\"Anveshika Manoj ,&nbsp;Mohammad K. Ahmad ,&nbsp;Gautam Prasad ,&nbsp;Durgesh Kumar ,&nbsp;Abbas A. Mahdi ,&nbsp;Manoj Kumar\",\"doi\":\"10.1016/j.prnil.2023.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Owing to the heterogeneous nature of prostate cancer (PCa) and errors in the characterization of the disease, researchers have been trying to unveil molecular biomarkers like microRNA (miRNA) as diagnostic markers. The purpose of our study is to demonstrate the precision of a panel of miRNAs as biomarkers with diagnostic potential for risk stratification.</p></div><div><h3>Materials and methods</h3><p>The present study demonstrates the comparative expression profiles of miRNA-141,-1290,-100, and -335 in both tissue and serum, including Benign Prostate Hyperplasia (BPH) and PCa, with healthy volunteers. Firstly, we demonstrate the expression of all miRNAs in the discovery cohort, including metastasis and benign tissue, and later validate their non-invasive diagnostic potential in BPH and PCa with healthy volunteers. MiRNA was isolated from tissue and serum to be quantified by RT-PCR and analyzed for biomarker potential by receiver operating characteristic (ROC) curve analysis, followed by targetome analysis of each miRNA.</p></div><div><h3>Results</h3><p>Among the non-invasive miRNA assessed, it was seen that miRNA 141 (<em>P</em> = 0.0003) and miRNA 1290 (<em>P</em> &lt; 0.0001) are oncogenic with significantly higher expression, while miRNA 100 (<em>P</em> = 0.0002) and miRNA 335 are tumor suppressor, in PCa as compared to controls. While for BPH, miRNA 141 (<em>P</em> = 0.003) and miRNA 335 (<em>P</em> = 0.0002) were found to be significantly oncogenic and tumor suppressors, respectively. The analysis of the ROC curve of panel miRNAs (miRNA-141,-1290, and -100) portrayed a significant area under the curve with greater sensitivity and specificity. Moreover, in-silico prediction of their respective targetomes represents their extensive involvement in PCa progression and various other cascades that aid in PCa networks.</p></div><div><h3>Conclusions</h3><p>To the best of our knowledge, we are going to report for the first time this panel of miRNA that can be used to accurately and efficiently diagnose BPH and PCa patients from healthy males.</p></div>\",\"PeriodicalId\":20845,\"journal\":{\"name\":\"Prostate International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/95/main.PMC10513910.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostate International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2287888223000326\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate International","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2287888223000326","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:由于癌症(PCa)的异质性和疾病特征的错误,研究人员一直试图揭示微小RNA(miRNA)等分子生物标志物作为诊断标志物。我们研究的目的是证明一组miRNA作为具有风险分层诊断潜力的生物标志物的准确性。材料和方法:本研究证明了miRNA-141、-1290、-100和-335在健康志愿者的组织和血清中的比较表达谱,包括良性前列腺增生症(BPH)和前列腺癌。首先,我们证明了发现队列中所有miRNA的表达,包括转移和良性组织,然后与健康志愿者一起验证了它们在前列腺增生和前列腺癌中的非侵入性诊断潜力。从组织和血清中分离出MiRNA,通过RT-PCR进行定量,并通过受体操作特征(ROC)曲线分析,然后对每种MiRNA进行靶向组分析,以分析生物标志物的潜力。结果:在评估的非侵入性MiRNA中,发现MiRNA 141(P=0.0003)、MiRNA 1290(P=0.0002)和MiRNA 335是肿瘤抑制因子,与对照组相比,在PCa中。而对于前列腺增生,miRNA 141(P=0.003)和miRNA 335(P=0.0002)分别被发现是显著的致癌和肿瘤抑制剂。对面板miRNA(miRNA-141、-1290和-100)的ROC曲线的分析显示,曲线下有一个显著的区域,具有更高的敏感性和特异性。此外,对它们各自靶体的计算机预测代表了它们广泛参与PCa进展和有助于PCa网络的各种其他级联反应。结论:据我们所知,我们将首次报道这组miRNA,它可用于准确有效地诊断健康男性前列腺增生和前列腺癌患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Screening and validation of novel serum panel of microRNA in stratification of prostate cancer

Screening and validation of novel serum panel of microRNA in stratification of prostate cancer

Screening and validation of novel serum panel of microRNA in stratification of prostate cancer

Screening and validation of novel serum panel of microRNA in stratification of prostate cancer

Background

Owing to the heterogeneous nature of prostate cancer (PCa) and errors in the characterization of the disease, researchers have been trying to unveil molecular biomarkers like microRNA (miRNA) as diagnostic markers. The purpose of our study is to demonstrate the precision of a panel of miRNAs as biomarkers with diagnostic potential for risk stratification.

Materials and methods

The present study demonstrates the comparative expression profiles of miRNA-141,-1290,-100, and -335 in both tissue and serum, including Benign Prostate Hyperplasia (BPH) and PCa, with healthy volunteers. Firstly, we demonstrate the expression of all miRNAs in the discovery cohort, including metastasis and benign tissue, and later validate their non-invasive diagnostic potential in BPH and PCa with healthy volunteers. MiRNA was isolated from tissue and serum to be quantified by RT-PCR and analyzed for biomarker potential by receiver operating characteristic (ROC) curve analysis, followed by targetome analysis of each miRNA.

Results

Among the non-invasive miRNA assessed, it was seen that miRNA 141 (P = 0.0003) and miRNA 1290 (P < 0.0001) are oncogenic with significantly higher expression, while miRNA 100 (P = 0.0002) and miRNA 335 are tumor suppressor, in PCa as compared to controls. While for BPH, miRNA 141 (P = 0.003) and miRNA 335 (P = 0.0002) were found to be significantly oncogenic and tumor suppressors, respectively. The analysis of the ROC curve of panel miRNAs (miRNA-141,-1290, and -100) portrayed a significant area under the curve with greater sensitivity and specificity. Moreover, in-silico prediction of their respective targetomes represents their extensive involvement in PCa progression and various other cascades that aid in PCa networks.

Conclusions

To the best of our knowledge, we are going to report for the first time this panel of miRNA that can be used to accurately and efficiently diagnose BPH and PCa patients from healthy males.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Prostate International
Prostate International Medicine-Urology
CiteScore
4.40
自引率
26.70%
发文量
40
审稿时长
35 days
期刊介绍: Prostate International (Prostate Int, PI), the official English-language journal of Asian Pacific Prostate Society (APPS), is an international peer-reviewed academic journal dedicated to basic and clinical studies on prostate cancer, benign prostatic hyperplasia, prostatitis, and ...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信